Compare Stocks: SQZ, ONCO, GNPX, and CRIS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$1.00 -8.3%	$2.82	$1.00 ▼ $35.15	$2.09M	3.01	129,234 shs	121,454 shs
GNPX Genprex	$3.45 -0.3%	$5.18	$3.26 ▼ $1,210.00	$2.83M	-0.94	49,848 shs	57,542 shs
ONCO Onconetix	$0.64 -3.7%	$0.78	$0.59 ▼ $209.50	$2.80M	2.68	577,813 shs	171,267 shs
SQZ SQZ Biotechnologies	$0.02	$0.02	$0.25 ▼ $3.56	$708K	2.34	455,220 shs	2,728 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	0.00%	-11.50%	-37.89%	-88.45%	-97.01%
GNPX Genprex	0.00%	+2.99%	-12.66%	-73.10%	-98.65%
ONCO Onconetix	0.00%	-15.52%	-4.20%	-32.30%	-99.59%
SQZ SQZ Biotechnologies	0.00%	0.00%	0.00%	0.00%	-14.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRIS Curis	$1.00 -8.3%	$2.82	$1.00 ▼ $35.15	$2.09M	3.01	129,234 shs	121,454 shs
GNPX Genprex	$3.45 -0.3%	$5.18	$3.26 ▼ $1,210.00	$2.83M	-0.94	49,848 shs	57,542 shs
ONCO Onconetix	$0.64 -3.7%	$0.78	$0.59 ▼ $209.50	$2.80M	2.68	577,813 shs	171,267 shs
SQZ SQZ Biotechnologies	$0.02	$0.02	$0.25 ▼ $3.56	$708K	2.34	455,220 shs	2,728 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRIS Curis	0.00%	-11.50%	-37.89%	-88.45%	-97.01%
GNPX Genprex	0.00%	+2.99%	-12.66%	-73.10%	-98.65%
ONCO Onconetix	0.00%	-15.52%	-4.20%	-32.30%	-99.59%
SQZ SQZ Biotechnologies	0.00%	0.00%	0.00%	0.00%	-14.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRIS Curis	2.00	Hold	$43.00	4,200.00% Upside
GNPX Genprex	1.00	Sell	N/A	N/A
ONCO Onconetix	1.00	Sell	N/A	N/A
SQZ SQZ Biotechnologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SQZ, ONCO, GNPX, and CRIS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
9/9/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/25/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/17/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/24/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $43.00
7/17/2026	CRIS Curis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRIS Curis	$9.44M	0.22	N/A	N/A	$8.45 per share	0.12
GNPX Genprex	N/A	N/A	N/A	N/A	$53.16 per share	N/A
ONCO Onconetix	$810K	3.46	N/A	N/A	$505.29 per share	0.00
SQZ SQZ Biotechnologies	$18.16M	0.04	N/A	N/A	$1.94 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRIS Curis	-$7.58M	-$14.22	N/A	N/A	N/A	-80.29%	-2,365.94%	-200.88%	11/5/2026 (Estimated)
GNPX Genprex	-$16.23M	-$133.36	N/A	N/A	N/A	N/A	-163.12%	-128.98%	12/2/2026 (Estimated)
ONCO Onconetix	-$14.03M	$248.12	0.00	N/A	N/A	-1,575.89%	-91.95%	-53.76%	11/12/2026 (Estimated)
SQZ SQZ Biotechnologies	-$79.46M	-$2.61	N/A	N/A	N/A	-369.96%	-119.83%	-59.90%	N/A

Latest SQZ, ONCO, GNPX, and CRIS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CRIS Curis	-$6.95	-$4.02	+$2.93	-$4.02	$1.00 million	N/A
8/14/2026	Q2 2026	GNPX Genprex	N/A	-$9.40	N/A	-$9.40	N/A	N/A
8/13/2026	Q2 2026	ONCO Onconetix	-$4,505.00	-$1.28	+$4,503.72	-$1.28	$0.02 million	$0.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRIS Curis	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A	N/A	N/A
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRIS Curis	N/A	0.49	0.49
GNPX Genprex	N/A	6.76	6.76
ONCO Onconetix	N/A	2.21	2.14
SQZ SQZ Biotechnologies	N/A	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRIS Curis	29.97%
GNPX Genprex	14.05%
ONCO Onconetix	23.89%
SQZ SQZ Biotechnologies	38.51%

Insider Ownership

Company	Insider Ownership
CRIS Curis	5.78%
GNPX Genprex	0.25%
ONCO Onconetix	0.27%
SQZ SQZ Biotechnologies	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRIS Curis	24	2.09 million	1.97 million	No Data
GNPX Genprex	13	820,000	818,000	No Data
ONCO Onconetix	2	4.38 million	4.37 million	N/A
SQZ SQZ Biotechnologies	1,620	29.49 million	24.77 million	Not Optionable

SQZ, ONCO, GNPX, and CRIS Headlines

Recent News About These Companies

Serica Energy gets Jefferies 'buy' rating and 320p price target

September 9, 2026 | proactiveinvestors.co.uk

SQZ Biotechnologies Co.

August 12, 2026 | barrons.com

Arsenal Yards attracts another life sciences tenant

April 23, 2026 | bizjournals.com

Financial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX)

March 22, 2026 | defenseworld.netD

Serica Energy reveals impact of Triton downtime, eyes volume recovery â€œsoonâ€

August 5, 2025 | proactiveinvestors.co.uk

SQZB SQZ Biotechnologies Company - Seeking Alpha

July 9, 2025 | seekingalpha.com

Serica Energy shares drop as Triton suspended until mid-March

February 18, 2025 | proactiveinvestors.co.uk

Serica Energy says 2025 outlook is â€˜promising'

January 21, 2025 | proactiveinvestors.co.uk

Serica Energy expects to remedy â€œclearly disappointingâ€ recent production performance

January 7, 2025 | proactiveinvestors.co.uk

SQZ Biotechnologies Co Ordinary Shares

December 23, 2024 | morningstar.comM

Portal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA Ventures

December 19, 2024 | finance.yahoo.com

Global Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsight

September 5, 2024 | prnewswire.co.ukP

STEMCELL Launches Novel Cell-Engineering CellPore™ Transfection System

August 1, 2024 | valdostadailytimes.comV

What is the price tag to keep the biotech engine humming in Massachusetts?

July 23, 2024 | msn.com

SQZ Biotechnologies Company (SQZB)

May 22, 2024 | finance.yahoo.com

Sqz Bio (SQZB) Earnings Dates & Reports

May 8, 2024 | investing.com

VC funding update: who raised money in March?

April 1, 2024 | bizjournals.com

SQZ, Portal founder Armon Sharei on starting over in biotech

March 26, 2024 | biopharmadive.comB

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

March 19, 2024 | finance.yahoo.com

SQZB SQZ Biotechnologies Company

December 28, 2023 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SQZ, ONCO, GNPX, and CRIS Company Descriptions

Curis NASDAQ:CRIS

$1.00 -0.09 (-8.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.06 +0.05 (+5.50%)

As of 09/18/2026 07:47 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Genprex NASDAQ:GNPX

$3.45 -0.01 (-0.29%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.50 +0.04 (+1.30%)

As of 09/18/2026 06:48 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Onconetix NASDAQ:ONCO

$0.64 -0.02 (-3.69%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.66 +0.02 (+2.97%)

As of 09/18/2026 07:55 PM Eastern

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

SQZ Biotechnologies NYSE:SQZ

$0.02 0.00 (0.00%)

As of 09/18/2026

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SQZ, ONCO, GNPX, and CRIS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SQZ, ONCO, GNPX, and CRIS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SQZ, ONCO, GNPX, and CRIS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SQZ, ONCO, GNPX, and CRIS Company Descriptions

Curis NASDAQ:CRIS

Genprex NASDAQ:GNPX

Onconetix NASDAQ:ONCO

SQZ Biotechnologies NYSE:SQZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SQZ, ONCO, GNPX, and CRIS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SQZ, ONCO, GNPX, and CRIS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SQZ, ONCO, GNPX, and CRIS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SQZ, ONCO, GNPX, and CRIS Company Descriptions

Curis NASDAQ:CRIS

Genprex NASDAQ:GNPX

Onconetix NASDAQ:ONCO

SQZ Biotechnologies NYSE:SQZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools